Humanigen Data Show Success In High-Risk COVID-19 Population
Lenzilumab Heads To FDA
Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.
You may also be interested in...
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
Drugs for ARDS in COVID-19 have yielded mixed results in the clinic, with Boehringer Ingelheim pulling one from Phase II development earlier this month.
Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.